Today’s Top Three in Pharma 021609

Takeda gets approval for Uloric – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced today that the United States Food and Drug Administration (FDA) has approved ULORIC® (febuxostat) 40 mg and 80 mg for the chronic management of hyperuricemia in patients with gout. This once-daily, oral medication is the first new treatment option in more than 40 years for the more than five million patients who have hyperuricemia associated with gout.

Diabetes drug Byetta tanking.

New head of Sanofi (Viehbacher) applying lessons learned at GSK.

PLUS – my review of last week’s ePharma Summit, and a sum-up of some recent articles (with links) on pharma e-marketing/social media.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff